January 8, 2013 • Volume 10 / Number 1
NCI Central Institutional Review Board Receives Accreditation
The Association for the Accreditation of Human Research Protection Programs (AAHRPP) recently awarded the NCI Central Institutional Review Board 
(CIRB) full accreditation. The CIRB provides a review process that can streamline local IRB reviews of national multicenter cancer treatment trials.
AAHRPP awards accreditation to organizations demonstrating the highest ethical standards in clinical research. Accreditation establishes that the NCI CIRB has robust review processes in place to ensure the safety and protection of people who participate in NCI-funded clinical studies.
The NCI CIRB is also changing to an independent review model. Under this model, research sites in different locations that have joined the NCI CIRB can rely solely on the CIRB to meet all IRB regulatory requirements, instead of undergoing a local IRB review.
A pilot study performed at 22 sites that conduct clinical research showed that participants enthusiastically supported the independent model. This model further reduces the administrative burden on local IRBs and investigators, shortens the time needed to start accruing participants, and, as a result, allows institutions to offer more clinical trials.
The change is part of the NCI national clinical trials network restructuring, which aims to reduce the length of time it takes to complete cancer clinical trials and bring new cancer treatments to patients.
(CIRB) full accreditation. The CIRB provides a review process that can streamline local IRB reviews of national multicenter cancer treatment trials.AAHRPP awards accreditation to organizations demonstrating the highest ethical standards in clinical research. Accreditation establishes that the NCI CIRB has robust review processes in place to ensure the safety and protection of people who participate in NCI-funded clinical studies.
The NCI CIRB is also changing to an independent review model. Under this model, research sites in different locations that have joined the NCI CIRB can rely solely on the CIRB to meet all IRB regulatory requirements, instead of undergoing a local IRB review.
A pilot study performed at 22 sites that conduct clinical research showed that participants enthusiastically supported the independent model. This model further reduces the administrative burden on local IRBs and investigators, shortens the time needed to start accruing participants, and, as a result, allows institutions to offer more clinical trials.
The change is part of the NCI national clinical trials network restructuring, which aims to reduce the length of time it takes to complete cancer clinical trials and bring new cancer treatments to patients.
No hay comentarios:
Publicar un comentario